Actinogen Medical Limited · ASX:ACW

Actinogen Medical — Technical Presentation (November 2026)

19 slides from Actinogen Medical's technical presentation, Nov 19, 2026

  1. Slide 1: Actinogen pivotal Alzheimer's trial demonstrates trends toward clinical benefit in older patients

    For personal use only ASX ANNOUNCEMENT Actinogen pivotal Alzheimer’s disease trial demonstrates trends toward clinical benefit in older patients and favourable longer term safety profile Sydney, 19 November 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) today announces topline results fro

  2. Slide 2: Interim analysis, OLE data, cash runway and CEO comment

    5. Unblinding of data used by the Independent Data Monitoring Committee (DMC) in January 2026, for its interim analysis of trial-futility, showed a statistically significant Xanamem treatment benefit of 0.58 points (p=0.03, n=88) on the prespecified, interim analysis Week 24 CDR-SB endpoint, which w

  3. Slide 3: About Actinogen Medical, XanaMIA trial and Xanamem

    Investors Media Dr Steven Gourlay Michael Roberts George Hazim CEO & Managing Director Communications Media & Public Affairs Australia P: +61 2 8964 7401 M: +61 423 866 231 M: +61 417 516 262 E. steven.gourlay@actinogen.com.au E. michael.roberts@actinogen.com.au E: georgehazim@mediaaffairs.com.au Fo

  4. Slide 4: XanaMIA Alzheimer's trial topline results webinar

    rsonal use only XanaMIA Alzheimer’s disease trial demonstrates clinically significant trend toward benefit in participants over 75 years but not in overall trial population Xanamem demonstrates good long-term safety and tolerability with a promising rate of disease slowing in older Alzheimer’s patie

  5. Slide 5: Disclaimer

    Disclaimer This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to mak

  6. Slide 6: rsonal use only

    rsonal use only XanaMIA results webinar 19 Nov 2026 3 XanaMIA results webinar 19 Nov 2026

  7. Slide 7: XanaMIA trial design and methods

    XanaMIA trial design and methods A double-blind, randomized, 36-week, 2-arm clinical trial to assess safety, tolerability, and efficacy of Xanamem 10 mg daily in patients with mild to moderate AD (MMSE 18-26) rsonal use only 10mg Xanamem Follow-up & Pre-screening Screening open label Placebo -10 -4

  8. Slide 8: Key baseline characteristics for overall population

    Key baseline characteristics for overall population Generally well-balanced between groups rsonal use only Xanamem Placebo Age (mean, SD) 75.4 (7.5) 73.4 (8.6) Sex, female (N, %) 63 (51.2) 57 (46.3) Concomitant AD medications, yes (N, %) 74 (60.2) 75 (61) ApoE4 carriers (N, %) 93 (75.6) 77 (62.6) MM

  9. Slide 9: Primary endpoint: small overall CDR-SB benefit

    Primary endpoint: small overall CDR-SB benefit Effect size 0.10 points at end of treatment, not statistically significant (p = 0.65 Week 36) rsonal use only Baseline Week 12 Week 24 Week 36 0 0.2 0.4 0.6 CDR-SB LS mean change 0.8 from baseline (± SE) 1 0.10-point benefit 1.2 1.4 Worsening 1.6 Xaname

  10. Slide 10: Major Xanamem trend in prespecified age above median

    Major Xanamem trend in prespecified age > 75 years CDR-SB effect size 0.39 points, p = 0.22 at Week 36 rsonal use only Age ≤ median at baseline Age > median at baseline Baseline Week 12 Week 24 Week 36 Baseline Week 12 Week 24 Week 36 0 0 0.2 0.2 30% slowing of CDR-SB LS mean change 0.4 0.4 from bas

  11. Slide 11: Clear benefits in response rates in older participants

    Clear benefits in response rates in older participants 40% Xanamem stable (no progression) vs. 22% Placebo for age > 75 years* rsonal use only *p = 0.02 50 45 40 40 37 35 30 24 Percentage responders 25 22 20 15 10 5 0 > 70 stable > 75 stable Xanamem Placebo For context, stable disease claim in donan

  12. Slide 12: Major unmet need in Alzheimer's care for older adults

    Major unmet need in Alzheimer’s care for adults older than 75 Alzheimer’s patients older than 75 represent more than two thirds of the market rsonal use only • 5.5 million Americans age 75+ live with Alzheimer’s, accounting for 74% of U.S. cases among adults 65 and older. [1] • ~80% of Alzheimer’s c

  13. Slide 13: Slight benefit of Xanamem on cognition

    Slight benefit of Xanamem on cognition Cognitive performance measured by computerized testing, p = 0.59 rsonal use only 0.1 0.05 0 Global CTB LS mean change from baseline (± SE) -0.05 -0.1 Worsening -0.15 Baseline Week 4 Week 12 Week 24 Week 36 Xanamem Placebo XanaMIA results webinar 19 Nov 2026 10

  14. Slide 14: Slight benefit on daily functioning overall

    Slight benefit on daily functioning overall A-IADL-Q-SV “Amsterdam” activities of daily living questionnaire rsonal use only 2 1.5 1 0.5 0 A-IADL-Q-SV LS mean change from baseline (± SE) -0.5 -1 -1.5 -2 Worsening -2.5 -3 Baseline Week 12 Week 24 Week 36 Xanamem (n=123) Placebo (n=123) XanaMIA result

  15. Slide 15: Other preliminary findings

    Other preliminary findings rsonal use only • Available data from the XanaMIA OLE phase indicates disease stabilization in the mean CDR-SB in the first 29 participants who have reached 24 weeks on active Xanamem • Trends towards reduction in neuroinflammation markers GFAP, neurofilament light • No tr

  16. Slide 16: The XanaMIA interim analysis was strongly positive

    The XanaMIA interim analysis was strongly positive Effect sizes 0.58 at Week 24, p = 0.03; 0.38 at Week 36, p = 0.39 rsonal use only Baseline Week 12 Week 24 Week 36 0 0.2 0.4 0.6 CDR-SB LS mean change from baseline (± SE) 0.8 1 1.2 1.4 1.6 Worsening Xanamem Placebo Week 12 Week 24 Week 36 n (Xaname

  17. Slide 17: Conclusion

    Conclusion • The Company sincerely thanks everyone who has supported Xanamem development up to this point rsonal use only including patients and their families living with Alzheimer’s disease, as well our shareholders • The risk-benefit profile of Xanamem is highly suited to treatment in mild to mod

  18. Slide 18: XanaMIA results webinar 19 Nov 2026

    rsonal use only XanaMIA XanaMIAresults resultswebinar webinar19 19Nov Nov2026 2026 15

  19. Slide 19: Contacts

    Contacts rsonal use only Will Souter Steven Gourlay CFO & Investor Relations CEO & Managing Director M: +61 402 035 716 P: +61 2 8964 7401 E. will.souter@actinogen.com.au E. steven.gourlay@actinogen.com.au Join the Actinogen Investor Hub: https://investors.actinogen.com.au/ XanaMIA results webinar 1

Actinogen Medical — Technical Presentation (November 2026) on 6ix